Delcath Systems (NASDAQ:DCTH) Stock Price Up 7.2% on Better-Than-Expected Earnings

Shares of Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) were up 7.2% during mid-day trading on Tuesday following a better than expected earnings announcement. The company traded as high as $21.84 and last traded at $21.7290. 533,561 shares were traded during trading, an increase of 14% from the average session volume of 468,296 shares. The stock had previously closed at $20.27.

The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.26. Delcath Systems had a net margin of 6.05% and a return on equity of 5.56%. The business had revenue of $35.10 million for the quarter, compared to analyst estimates of $25.99 million.

Trending Headlines about Delcath Systems

Here are a few of the latest headlines about DCTH:

  • Positive Sentiment: Delcath reported quarterly EPS of $0.17, versus analyst expectations for a loss of $0.09, and revenue of $35.1 million, well ahead of the $26.0 million consensus estimate. The strong results helped propel shares to a 12-month high. Delcath Systems Sets New 12-Month High After Strong Earnings
  • Neutral Sentiment: Delcath provided fourth-quarter 2026 earnings guidance, but the available report does not include the guidance figures or how they compare with expectations. Delcath Systems Provides Fourth-Quarter 2026 Earnings Guidance
  • Negative Sentiment: HC Wainwright trimmed its Q2 2027 EPS forecast to $0.11 from $0.12, a small near-term estimate reduction that contrasts with its higher longer-term projections.

Wall Street Analysts Forecast Growth

Several analysts have commented on DCTH shares. Zacks Research lowered Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. HC Wainwright boosted their price objective on Delcath Systems from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday. BTIG Research upped their target price on Delcath Systems from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday. Weiss Ratings lowered Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Finally, Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.33.

View Our Latest Report on Delcath Systems

Institutional Investors Weigh In On Delcath Systems

A number of large investors have recently modified their holdings of DCTH. Bank of New York Mellon Corp acquired a new stake in shares of Delcath Systems in the second quarter valued at about $1,362,000. Bank of America Corp DE boosted its position in Delcath Systems by 54.0% during the first quarter. Bank of America Corp DE now owns 57,729 shares of the company’s stock worth $536,000 after acquiring an additional 20,249 shares during the last quarter. IFP Advisors Inc acquired a new position in Delcath Systems during the second quarter worth about $52,000. Russell Investments Group Ltd. grew its stake in Delcath Systems by 31.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock valued at $1,417,000 after acquiring an additional 21,069 shares in the last quarter. Finally, Alps Advisors Inc. grew its stake in Delcath Systems by 30.3% during the 3rd quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock valued at $729,000 after acquiring an additional 10,600 shares in the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Performance

The company has a market cap of $755.40 million, a PE ratio of 136.06 and a beta of 0.62. The firm’s 50 day moving average is $15.71 and its 200-day moving average is $12.59.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

See Also

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.